Cargando…

Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy

BACKGROUND: The purpose of this study was to determine the factors that increase the risk of fatal thrombotic events in hospitalized coronavirus disease 2019 (COVID-19) patients receiving standard therapy according to the National Clinical Practice Guidelines (National Guidelines). MATERIALS AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaliyeva, Sholpan, Yukhnevich, Yekaterina, Myasnikova, Zhanna, Simokhina, Natalya, Dyussembaeva, Nailya, Bikbatyrova, Yuliya, Drobchenko, Yelena, Sagadatova, Torgin, Semenikhina, Polina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688589/
https://www.ncbi.nlm.nih.gov/pubmed/38044972
http://dx.doi.org/10.4103/jfcm.jfcm_60_23
_version_ 1785152196373905408
author Kaliyeva, Sholpan
Yukhnevich, Yekaterina
Myasnikova, Zhanna
Simokhina, Natalya
Dyussembaeva, Nailya
Bikbatyrova, Yuliya
Drobchenko, Yelena
Sagadatova, Torgin
Semenikhina, Polina
author_facet Kaliyeva, Sholpan
Yukhnevich, Yekaterina
Myasnikova, Zhanna
Simokhina, Natalya
Dyussembaeva, Nailya
Bikbatyrova, Yuliya
Drobchenko, Yelena
Sagadatova, Torgin
Semenikhina, Polina
author_sort Kaliyeva, Sholpan
collection PubMed
description BACKGROUND: The purpose of this study was to determine the factors that increase the risk of fatal thrombotic events in hospitalized coronavirus disease 2019 (COVID-19) patients receiving standard therapy according to the National Clinical Practice Guidelines (National Guidelines). MATERIALS AND METHODS: In this case–control study, cases included 83 adults with COVID-19 who had died from thrombosis and controls comprised 83 COVID-19 patients with comparable criteria who survived. Data was abstracted by reviewing the medical records of selected patients and analyzed using Statistica. Parametric and non-parametric tests, as appropriate, were used to compare continuos variables between cases and controls, whereas Chi-square test was employed to compare categorical variables. Odds ratio (OR) was also calculated to measure the strength of association of case status and various independent variables. RESULTS: Fatal outcomes were higher in patients with chronic tubulointerstitial nephritis, (OR = 2.4, 95% CI 1.2–4.9); obesity, (OR = 2.1, 95% CI 0.5–8.6); and coronary heart disease (OR = 1.6, 95% CI 0.8–3.2). In the group with a D-dimer level from 250 to 1000 ng/ml, a statistically significant moderate positive correlation was found between the day of death and D-dimer level (P = 0.026). The lack of use of the PADUA Prediction Score for the risk of venous thromboembolism scale (PADUA Scale) and control of laboratory parameters (APTT and D-dimer) were associated with increased risk of fatal outcome. Overall, 19.2% cases and 8.4% of controls had no coagulation control; (OR = 2.6, 95% CI 1–6.7). CONCLUSION: Chronic tubulointerstitial nephritis, obesity, and coronary heart disease were associatied with fatal thrombosis. A slight elevation of D-dimer level, lack of the PADUA Scale and laboratory monitoring in the management of hospitalized patients with COVID-19. was associated with an increased risk of thromboembolism.
format Online
Article
Text
id pubmed-10688589
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-106885892023-12-01 Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy Kaliyeva, Sholpan Yukhnevich, Yekaterina Myasnikova, Zhanna Simokhina, Natalya Dyussembaeva, Nailya Bikbatyrova, Yuliya Drobchenko, Yelena Sagadatova, Torgin Semenikhina, Polina J Family Community Med Original Article BACKGROUND: The purpose of this study was to determine the factors that increase the risk of fatal thrombotic events in hospitalized coronavirus disease 2019 (COVID-19) patients receiving standard therapy according to the National Clinical Practice Guidelines (National Guidelines). MATERIALS AND METHODS: In this case–control study, cases included 83 adults with COVID-19 who had died from thrombosis and controls comprised 83 COVID-19 patients with comparable criteria who survived. Data was abstracted by reviewing the medical records of selected patients and analyzed using Statistica. Parametric and non-parametric tests, as appropriate, were used to compare continuos variables between cases and controls, whereas Chi-square test was employed to compare categorical variables. Odds ratio (OR) was also calculated to measure the strength of association of case status and various independent variables. RESULTS: Fatal outcomes were higher in patients with chronic tubulointerstitial nephritis, (OR = 2.4, 95% CI 1.2–4.9); obesity, (OR = 2.1, 95% CI 0.5–8.6); and coronary heart disease (OR = 1.6, 95% CI 0.8–3.2). In the group with a D-dimer level from 250 to 1000 ng/ml, a statistically significant moderate positive correlation was found between the day of death and D-dimer level (P = 0.026). The lack of use of the PADUA Prediction Score for the risk of venous thromboembolism scale (PADUA Scale) and control of laboratory parameters (APTT and D-dimer) were associated with increased risk of fatal outcome. Overall, 19.2% cases and 8.4% of controls had no coagulation control; (OR = 2.6, 95% CI 1–6.7). CONCLUSION: Chronic tubulointerstitial nephritis, obesity, and coronary heart disease were associatied with fatal thrombosis. A slight elevation of D-dimer level, lack of the PADUA Scale and laboratory monitoring in the management of hospitalized patients with COVID-19. was associated with an increased risk of thromboembolism. Wolters Kluwer - Medknow 2023 2023-10-13 /pmc/articles/PMC10688589/ /pubmed/38044972 http://dx.doi.org/10.4103/jfcm.jfcm_60_23 Text en Copyright: © 2023 Journal of Family and Community Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Kaliyeva, Sholpan
Yukhnevich, Yekaterina
Myasnikova, Zhanna
Simokhina, Natalya
Dyussembaeva, Nailya
Bikbatyrova, Yuliya
Drobchenko, Yelena
Sagadatova, Torgin
Semenikhina, Polina
Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy
title Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy
title_full Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy
title_fullStr Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy
title_full_unstemmed Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy
title_short Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy
title_sort risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (covid-19) patients on anticoagulant therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688589/
https://www.ncbi.nlm.nih.gov/pubmed/38044972
http://dx.doi.org/10.4103/jfcm.jfcm_60_23
work_keys_str_mv AT kaliyevasholpan riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy
AT yukhnevichyekaterina riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy
AT myasnikovazhanna riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy
AT simokhinanatalya riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy
AT dyussembaevanailya riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy
AT bikbatyrovayuliya riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy
AT drobchenkoyelena riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy
AT sagadatovatorgin riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy
AT semenikhinapolina riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy